Are there clinically important differences between beta-blockers in heart failure?
Cleland
John G F
JG
University of Hull, Castle Hill Hospital, Kingston-upon-Hull, UK. g.m.porter@hull.ac.uk <g.m.porter@hull.ac.uk>
Loh
Huan
H
Windram
Jonathan
J
D000319:Adrenergic beta-Antagonists / Q000145:classification* / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002227:Carbazoles / Q000627:therapeutic use; D000077261:Carvedilol; D004304:Dosage Forms; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D006321:Heart / Q000187:drug effects; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008790:Metoprolol / Q000627:therapeutic use; D011412:Propanolamines / Q000627:therapeutic use; D016019:Survival Analysis; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D004304:Dosage Forms; D011412:Propanolamines; D000077261:Carvedilol; D008790:Metoprolol